Monthly Archives: February 2022
EVALUATING THE IMPACT OF THE COVID-19 PANDEMIC ON URGENT MEDICAL ACCESS FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE AT A PRIVATE COMMUNITY GASTROENTEROLOGY PRACTICE
Patients with inflammatory bowel disease (IBD) are subject to frequent emergency department (ED) visits. In order to decrease unnecessary ED utilization, we established an urgent care hotline (IBD URGENT) at a private community gastroenterology practic… Continue reading
SEROLOGICAL RESPONSES TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY
The immune response of SARS-CoV-2 vaccines is uncertain in those with Inflammatory Bowel Disease (IBD) due to a diverse array of immune-modifying therapies that vary in the mechanism of immunosuppression. Continue reading
DIET AND ITS MICROENVIRONMENT INFLUENCE THE HEALTH OF COLON
Ulcerative colitis (UC) is an autoimmune chronic inflammatory disease of the large intestine that greatly increases risks of colorectal cancer. UC is an idiopathic inflammatory disorder of the colonic mucosa, which starts in the rectum and generally ex… Continue reading
PREDICTORS OF CLINICAL RELAPSE AMONG PATIENTS WITH ULCERATIVE COLITIS IN ENDO-HISTOLOGIC REMISSION
In patients with ulcerative colitis (UC), endo-histologic (deep) remission has been increasingly recognized to reduce the risk of clinical relapse above and beyond attainment of endoscopic remission alone. However, relapse rates among patients in deep … Continue reading
ADVERSE CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING DIFFERENT SEQUENCES OF FIRST- AND SECOND-LINE BIOLOGIC TREATMENTS: FINDINGS FROM ROTARY
Inadequate response, loss of response, or intolerance to a first-line biologic typically requires patients with ulcerative colitis (UC) to switch treatment to a second-line biologic therapy. However, the clinical outcomes of patients receiving differen… Continue reading
INCIDENCE AND PREVALENCE OF PRIMARY SCLEROSING CHOLANGITIS: A META-ANALYSIS OF POPULATION-BASED STUDIES
Primary sclerosing cholangitis (PSC) is a chronic liver disease associated with significant morbidity, mortality and healthcare utilization—with nearly 80% of PSC patients having inflammatory bowel disease (IBD). Understanding the incidence of PSC is i… Continue reading
MIRIKIZUMAB IMPROVES PATIENT ASSESSMENT OF DISEASE SEVERITY AND CHANGE IN DISEASE ACTIVITY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
Mirikizumab (miri), an anti-IL-23p19 inhibitor, has demonstrated efficacy in patients with ulcerative colitis and moderately to severely active Crohn’s disease (CD) in a Phase 2, randomised, double-blind, placebo-controlled study (NCT02891226). This an… Continue reading
IMPACT OF CURRENT AND FORMER SMOKING ON THE RISK OF ULCERATIVE COLITIS AMONG FAMILY HISTORY POSITIVE AND NEGATIVE INDIVIDUALS; EVIDENCE FOR GENE-SMOKING INTERACTION FROM LARGE SCALE POPULATION-BASED COHORT STUDY IN KOREA
The interaction between smoking and genetic predispositions in the pathogenesis of ulcerative colitis (UC) remains to be determined. Also the effect of smoking on UC in Asian populations is not well-studied. Continue reading
VEDOLIZUMAB AS TREATMENT FOR COMMON VARIABLE IMMUNE DEFICIENCY (CVID): A CASE SERIES AND BRIEF REVIEW OF THE LITERATURE
Common variable immunodeficiency (CVID) is the most common symptomatic immunodeficiency, frequently presenting as recurrent upper respiratory infections. A portion of these patients develop non-specific gastrointestinal symptoms with a smaller subset d… Continue reading
GLOBAL HOSPITALIZATION TRENDS FOR CROHN’S DISEASE AND ULCERATIVE COLITIS: SYSTEMATIC REVIEW WITH TEMPORAL ANALYSES
The evolving epidemiologic patterns of IBD throughout the world, in conjunction with advances in therapeutic treatments, may influence hospitalization rates of IBD in the 21st century. We performed a systematic review with temporal analysis of hospital… Continue reading